- Home
- RYN vs AKRO Comparison
RYN vs AKRO Comparison
Compare RYN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYN | AKRO |
|---|---|---|
| Founded | 1926 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RYN | AKRO |
|---|---|---|
| Price | $21.51 | $54.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $27.25 | ★ $73.56 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | ★ 13.44% | N/A |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $1,293,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.42 | ★ N/A |
| Revenue Growth | ★ 60.70 | N/A |
| 52 Week Low | $21.06 | $21.34 |
| 52 Week High | $32.07 | $58.40 |
Technical Indicators
Market Signals| Indicator | RYN | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 66.54 |
| Support Level | $21.19 | $54.22 |
| Resistance Level | $22.29 | $54.70 |
| Average True Range (ATR) | 0.44 | 0.14 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 39.84 | 64.18 |
Price Performance
Historical ComparisonAbout RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.